| abstract |
Isolated peptide comprising an amino acid sequence selected from SRFKVWWAAG (SEQ ID NO:55), ARFKVWWAAG (SEQ ID NO:56), SAFKVWWAAG (SEQ ID NO:57), SRFKAWWAAG (SEQ ID NO:60), SRFKVAWAAG (SEQ ID NO:61), SRFKVWAAAG (SEQ ID NO:62), SRFKVWWAAG (SEQ ID NO:63), SRFKVWWAAG (SEQ ID NO:64), RFKVWWAAG (SEQ ID NO:65), SRFKVWWAG (SEQ ID NO:68), SRFKVWWG (SEQ ID NO:69), or from SRFKVWWG (SEQ ID NO:73), SRFKVWWG (SEQ ID NO:74), ARFKVWWG (SEQ ID NO:75), ARFKVWWG (SEQ ID NO:76), ARFKVWWGG (SEQ ID NO:77), ARFKVWWGG (SEQ ID NO:78), ARFKVWWA (SEQ ID NO:79), ARFKVWWA (SEQ ID NO:80), ARFKVWWAA (SEQ ID NO:81) and ARFKVWWA(CONH 2 ) (SEQ ID NO:82), or an amino acid sequence, which is SRFKVWWAAG (SEQ ID NO:1. The novel peptides are capable of binding to human kallikrein 2 and of inhibiting the proteolytic activity of human kallikrein 2. They can be used in prostate cancer treatment as such or in combination with other ligands modulating the activity of factors mediating tumor growth. |